Sangamo BioSciences | SGMO - Ebitda


Sangamo BioSciences reported $-67.97M in EBITDA for its fiscal quarter ending in June of 2023.





Ebitda Change Date
Alaunos Therapeutics USD -21.02M 1.33M Mar/2021
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Alterity Therapeutics Limited AUD -7.72M 2.99M Jun/2023
Amgen USD 5.14B 775M Dec/2025
Bayer EUR 4.45B 2.49B Mar/2026
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
Biogen USD 649.7M 76.5M Mar/2026
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Cipla INR 9.55B 3B Mar/2026
Clal Biotechnology ILS -5.3M 2.09M Dec/2022
Compugen USD -9.02M 1.12M Mar/2026
CSL USD 3.13B 1.17B Dec/2025
Gilead Sciences USD 3.02B 1.01B Dec/2025
GlaxoSmithKline GBP 2.77B 1.65B Mar/2026
Grifols EUR 482.04M 7.04M Sep/2025
Ionis Pharmaceuticals USD -200.02M 42.89M Dec/2025
J&J USD 7.19B 2.32B Dec/2025
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Merck USD 6.3B 2.09B Dec/2025
Novartis USD 5.3B 530M Mar/2026
Omeros USD -47.96M 7.39M Sep/2023
Pfizer USD 5.99B 5.23B Mar/2026
Roche Holding CHF 12.68B 2.36B Jun/2024
Sanofi EUR 3.31B 3.65B Mar/2026
Sarepta Therapeutics USD -252.2M 84.16M Dec/2025
Tectonic Therapeutic USD -21.18M 365K Dec/2025
Ultragenyx Pharmaceutical USD -99.43M 57.35M Dec/2025
Vertex Pharmaceuticals USD 1.19B 195.3M Mar/2026